Next-Generation Nobivac® Protection For Cats
A complete portfolio of vaccines that deliver robust efficacy with a proven safety profile
Nobivac NXT® Feline: Designed With Cats In Mind
Rapid 1-week onset of immunity (OOI)*
Low-volume doses (0.5 mL)
Adjuvant-free formulations
FeLV Protection built on RNA particle technology
Combination products for fewer injections
1 to 3-year duration of immunity (DOI)*
Proven safety profile for kittens and cats†
Approved for concurrent (non-mixed) use with Nobivac® Rabies
Real-world results‡
* Chlamydia felis has a 1-year DOI.
† First dose from 8 weeks of age.
‡Nobivac NXT® FeLV has been administered in cats across North America since 2024.
Featuring the first major advancement in feline vaccine technology in over 20 years
Innovative Technology, Robust Immune Response
By triggering a robust antibody and cellular immune response without the use of an adjuvant, RNA particle technology offers an innovative way to deliver next-level protection for cats for FeLV.
One Range, Flexible Solutions
Nobivac NXT® HCP
Protects against feline herpesvirus, feline calicivirus and panleucopaenia virus.
Nobivac NXT® HC
Protects against feline herpesvirus and feline calicivirus.
Nobivac NXT® FeLV
Protects against feline leukaemia virus.
Nobivac NXT® HCPFeLV
Protects against feline herpesvirus, feline calicivirus, panleucopaenia virus and feline leukaemia virus.
Nobivac NXT® HCPChFeLV
Protects against feline herpesvirus, feline calicivirus, panleucopaenia virus, feline leukaemia virus and Chlamydia felis.
Robust Efficacy, Proven Safety Profile
Explore the studies and see what Nobivac NXT® Feline can do for your patients.
Laboratory overdose/repeat-dose studies1
STUDY DESIGN:
Studies in cats were performed to assess safety of a single and repeated dose (n=11 vaccinates, n=5 controls), two studies into safety of an overdose of viral components (n=10 vaccinates and n=11 vaccinates, n=5 controls, respectively) and a specific FPL overdose safety study (n=5). Studies used specific-pathogen-free kittens of 8 to 9 weeks of age.
Daily monitoring of:
- Injection sites
- Clinical observation
- Body temperature measurements
Results1
No serious adverse events were observed in any of the studies.
- Pyrexia occurred most often after the first vaccination and was more consistent following overdose administrations, resolving within two days in all studies.
- Injection site reactions were the most frequent local reaction observed. These were small and short lived after maximum dosing and more frequent and of greater size and duration after administration of an overdose, but generally diffuse, not warm and not painful and without chronic progression.
Field study1
STUDY DESIGN:
Safety was assessed in a field study comparing concurrent (non-mixed) use with rabies vaccination vs a positive control regimen – 71 healthy kittens (8 weeks old) and 71 healthy adult cats (>1 year old) of various (mixed) breeds allocated randomly to either test or control group.
Daily monitoring of:
- Injection sites
- Systemic reactions
- Rectal temperature
Results1
No serious adverse events were observed in any of the studies.
- Vaccination was well tolerated in both adult cats and kittens.
- Rectal temperatures did not show clinically relevant changes.
- No injection site reactions were observed in any animal from the test group following either the first or second vaccination.
One kitten in the test group experienced a mild adverse event consisting of reduced activity for one day, occurring 10 days after the second vaccination.
The Nobivac NXT® Feline Difference
All trademarks are property of their respective owners.
Designed to Fit Your Practice
Your MSD Animal Health representative can help you find out how this range can be tailored to your practice and patient needs.
Featured Products
Discover what is possible with next-level protection
Please fill out the form below to receive the latest information.
“*” indicates required fields
References
- Huisman W, Mommen A, Basten S, Driessen K, Pepels P, Cao Q, Holtslag H, Bourgeois M. and Pearce J. (2026). Development of a new feline combination vaccine including a novel RNA particle vaccine against feline leukemia virus. Vaccines, 14(7), 625. https://www.mdpi.com/2076-393X/14/7/625
- PUREVAX® feline vaccines. Summaries of Product Characteristics. October 2023.
- Leucofeligen® FeLV/RCP. Summary of Product Characteristics. December 2025.
- Versifel® FeLV available in ROI. Versifel® CVR available in NI . See Summary of Product Characteristics dated Oct 2023 and Jan 2025 respectively.